SCHEMBL21267702

SCHEMBL21267702

CC(C)c1ccc(CNS(C)(=O)=O)cn1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.45
TP53 P04637 1/20 0.40
NAMPT P43490 1/20 0.39
POLB P06746 2/20 0.39
KDM4E B2RXH2 1/20 0.39
TSHR P16473 1/20 0.39
RECQL P46063 1/20 0.39
LMNA P02545 1/20 0.37
GRIA2 P42262 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
NR1H2 P55055 1/20 0.35
NR1H3 Q13133 1/20 0.35
CHRNA7 P36544 1/20 0.35
CNR2 P34972 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HTT P42858 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21266984 0.86 CA1 (0.47) TP53LMNASMN1; SMN2CHRNA7ALDH1A1
SCHEMBL23114318 0.78 CHRNA7 (0.40) TP53NR1H2NR1H3CHRNA7
SCHEMBL24632527 0.78 KMT2A (0.49) KMT2ANAMPTPOLBKDM4ETSHR
SCHEMBL12986309 0.78 ESR1 (0.39) KMT2AKDM4ENPC1RAB9A
SCHEMBL18291414 0.77 KMT2A (0.47) KMT2ATP53NAMPTPOLBKDM4E
SCHEMBL5008265 0.77 KMT2A (0.56) KMT2ANAMPTKDM4ESMN1; SMN2NPC1
SCHEMBL4327907 0.75 ADH1B (0.43) KMT2ANPC1RAB9ACHRNA7CNR2
SCHEMBL24837402 0.75 ESR1 (0.38) NR1H2NR1H3CHRNA7
SCHEMBL19323038 0.74 KMT2A (0.47) KMT2APOLBKDM4ESMN1; SMN2NPC1
SCHEMBL5013529 0.74 NAMPT (0.48) KMT2ANAMPTKDM4ELMNACNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230062022-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS NUVATION BIO INC (US) 2023-03-02 US disclosed
US-11174252-B2 Heterocyclic compounds as kinase inhibitors NUVATION BIO INC. (US) 2021-11-16 US disclosed
US-20190248774-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) 2019-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11174252-B2 Heterocyclic compounds as kinase inhibitors CDK6, CDK4, CDK9 KMT2A 548/4885TP53 348/4885NAMPT 631/4885
US-20190248774-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK4, CDK6, CDK8 KMT2A 448/4885TP53 178/4885NAMPT 304/4885
US-20230062022-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK4, CDK6, CDK8 KMT2A 448/4885TP53 178/4885NAMPT 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.